EGFR and non-small cell lung carcinoma: According to the cost-effectiveness threshold criteria of the World Health Organization, Aguiar et al. reported that osimertinib is not, in fact, a cost-effective first-line therapy for advanced EGFR mutation-positive NSCLC [20].